Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
4 studies found for:    23146246 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed An Eight-week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Generalized Anxiety Disorder
Condition: Anxiety Disorders
Interventions: Drug: SSR149415;   Drug: Placebo;   Drug: Paroxetine
2 Completed An Eight-Week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Major Depressive Disorder
Condition: Depressive Disorder
Intervention: Drug: SSR149415
3 Completed Evaluation of the Potential Effects of SSR149415 on the Hypothalamic-pituitary-adrenal Axis in Outpatients With Major Depressive Disorder
Condition: Major Depressive Disorder
Interventions: Drug: VASOPRESSIN V1B RECEPTOR ANTAGONIST (SSR149415);   Drug: Placebo
4 Completed An Eight-Week Study Evaluating the Efficacy of Two Fixed Doses (250 mg Twice Daily and 100 mg Twice Daily) of SSR149415 in Patients With Major Depressive Disorder
Condition: Depressive Disorder
Intervention: Drug: SSR149415

Indicates status has not been verified in more than two years